Ticagrelor + Clopidogrel
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction, No-Reflow Phenomenon
Trial Timeline
Dec 1, 2014 → Dec 1, 2016
NCT ID
NCT02233790About Ticagrelor + Clopidogrel
Ticagrelor + Clopidogrel is a approved stage product being developed by AstraZeneca for Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT02233790. Target conditions include Myocardial Infarction, No-Reflow Phenomenon.
What happened to similar drugs?
9 of 20 similar drugs in Myocardial Infarction were approved
Approved (9) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04069234 | Phase 3 | Withdrawn |
| NCT03437044 | Approved | Completed |
| NCT02617290 | Phase 3 | Completed |
| NCT02663713 | Approved | Completed |
| NCT02319941 | Phase 2 | Completed |
| NCT02457130 | Approved | UNKNOWN |
| NCT02379676 | Approved | UNKNOWN |
| NCT02121288 | Approved | Withdrawn |
| NCT02233790 | Approved | UNKNOWN |
| NCT02618733 | Pre-clinical | Completed |
| NCT02052635 | Approved | Terminated |
| NCT01826175 | Approved | Withdrawn |
| NCT01864005 | Approved | Completed |
| NCT01732822 | Phase 3 | Completed |
| NCT01706510 | Approved | Completed |
| NCT01603082 | Approved | Completed |
| NCT01523366 | Approved | Completed |
| NCT01523392 | Approved | Completed |
| NCT01118325 | Phase 2 | Completed |
| NCT00391872 | Phase 3 | Completed |
Competing Products
20 competing products in Myocardial Infarction